Foreword| Volume 13, ISSUE 3, P341-342, May 2019

From the editor: Atherosclerosis in different flavors

      Does atherosclerosis come in different flavors? A longstanding rule in atherosclerosis pathology is that plaques develop along the same pattern regardless of the dominant risk factor(s) driving the process. Thus atherosclerosis in hypercholesterolemia cannot be distinguished pathologically from atherosclerosis in diabetes with high triglycerides and low HDL, and atherosclerosis in a patient with lupus looks pretty much the same.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rallidis L.S.
        • Kosmas N.
        • Tsirebolos G.
        • Rallidi M.
        • Kiouri E.
        • Kalpakos D.
        Prevalence of heterozygous familial hypercholesterolaemia and combined hyperlipidaemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
        J Clin Lipidol. 2019; 13: 502-508
        • Toutouzas K.
        • Skoumas J.
        • Koutagiar I.
        • et al.
        Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia.
        J Clin Lipidol. 2018; 12: 33-43
        • Bhatt D.L.
        • Steg P.G.
        • Miller M.
        • et al.
        Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
        N Engl J Med. 2019; 380: 11-22
        • Alfaddagh A.
        • Elajami T.K.
        • Saleh M.
        • et al.
        The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: a secondary analysis of a randomized clinical trial.
        J Clin Lipidol. 2018; 12: 937-947
        • Sniderman A.D.
        Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Cholesterol Guidelines get apoB right?.
        J Clin Lipidol. 2019; 13: 360-366
        • Grundy S.M.
        • Stone N.J.
        Elevated apolipoprotein B as a risk enhancing factor in the 2018 Cholesterol Guidelines.
        J Clin Lipidol. 2019; 13: 356-359
        • Wilson D.P.
        • Jacobson T.A.
        • Jones P.H.
        • et al.
        Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A Scientific Statement from the National Lipid Association.
        J Clin Lipidol. 2019; 13: 374-392
        • Jacobson T.A.
        • Cheeley M.K.
        • Jones P.H.
        • et al.
        The STatin Adverse Treatment Experience (STATE) survey: experience of patients reporting side effects of statin therapy.
        J Clin Lipidol. 2019; 13: 415-424